Is PSCBF or QYLD a better dividend investment in 2026?

PSCBF currently yields 1818.18% with a 5% 5-year dividend growth rate. QYLD yields 11.92% with -2.1% growth. The better choice depends on your goal: PSCBF offers higher current income.

What is the dividend yield difference between PSCBF and QYLD?

PSCBF has a forward dividend yield of 1818.18% ($2.00/share annually). QYLD yields 11.92% ($2.04/share annually). The yield gap is 1806.26 percentage points.

Home › Compare › PSCBF vs QYLD

PSCBF vs QYLD: Dividend Comparison 2026

PSCBF yields 1818.18% · QYLD yields 11.92%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 PSCBF wins by $4103414683.81M in total portfolio value

INVESTMENT

TIME HORIZON10 years

PSCBF

● Live price

1818.18%

Share price

$0.11

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$4103414683.84M

Annual income

$3,702,796,788,756,407.00

Full PSCBF calculator →

QYLD

Global X Nasdaq 100 Covered Call ETF

● Live price

11.92%

Share price

$17.15

Annual div

$2.04

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$25.4K

Annual income

$5,659.31

Full QYLD calculator →

Portfolio growth — PSCBF vs QYLD

📍 PSCBF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	PSCBF	QYLD
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, PSCBF + QYLD cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

PSCBF pays

QYLD pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PSCBF

Annual income on $10K today (after 15% tax)

$154,545.45/yr

After 10yr DRIP, annual income (after tax)

$3,147,377,270,442,946.00/yr

QYLD

Annual income on $10K today (after 15% tax)

$1,013.51/yr

After 10yr DRIP, annual income (after tax)

$4,810.41/yr

At 15% tax rate, PSCBF beats the other by $3,147,377,270,438,135.50/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PSCBF + QYLD for your $10,000?

PSCBF: 50%QYLD: 50%

100% QYLD50/50100% PSCBF

Portfolio after 10yr

$2051707341.93M

Annual income

$1,851,398,394,381,033.20/yr

Blended yield

90.24%

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PSCBF buys

QYLD buys

Politician	Chamber	Ticker	Type	Amount	Date
Tim Moore	🏢 House	$QYLD	▼ Sell	$15,001 - $50,000	2025-05-02
Tim Moore	🏢 House	$QYLD	▲ Buy	$15,001 - $50,000	2025-04-07
Dwight Evans	🏢 House	$QYLD	▼ Sell	$1,001 - $15,000	2022-11-14
Dwight Evans	🏢 House	$QYLD	▼ Sell	$1,001 - $15,000	2020-10-29

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricPSCBFQYLD

Forward yield	1818.18% ✓	11.92%
Annual dividend / share	$2.00	$2.04 ✓
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	0%
Portfolio after 10y	$4103414683.84M ✓	$25.4K
Annual income after 10y	$3,702,796,788,756,407.00 ✓	$5,659.31
Total dividends collected	$4074760433.31M ✓	$27.1K
Payment frequency	quarterly	monthly
Sector	Stock	ETF

Year-by-year: PSCBF vs QYLD ($10,000, DRIP)

Year	PSCBF Portfolio	PSCBF Income/yr	QYLD Portfolio	QYLD Income/yr	Gap
1← crossover	$192,518	$181,818.18	$10,352	$1,192.36	+$182.2K → PSCBF
2	$3,477,331	$3,271,336.99	$10,830	$1,347.57	+$3.47M → PSCBF
3	$58,943,217	$55,222,471.89	$11,460	$1,539.07	+$58.93M → PSCBF
4	$937,891,469	$874,822,227.57	$12,275	$1,777.84	+$937.88M → PSCBF
5	$14,012,869,532	$13,009,325,660.38	$13,323	$2,078.95	+$14012.86M → PSCBF
6	$196,647,994,247	$181,654,223,846.76	$14,667	$2,463.34	+$196647.98M → PSCBF
7	$2,592,865,386,485	$2,382,452,032,641.56	$16,396	$2,960.57	+$2592865.37M → PSCBF
8	$32,132,661,421,271	$29,358,295,457,731.54	$18,631	$3,612.97	+$32132661.40M → PSCBF
9	$374,409,247,740,494	$340,027,300,019,734.44	$21,548	$4,482.15	+$374409247.72M → PSCBF
10	$4,103,414,683,838,736	$3,702,796,788,756,407.00	$25,398	$5,659.31	+$4103414683.81M → PSCBF

PSCBF vs QYLD: Complete Analysis 2026

PSCBF — Stock

Pascal Biosciences Inc., a biotechnology company, engages in the research and development of products for the treatment of cancer, and for the improvement of the immune system. The company's development portfolio includes PAS-403, a mitosis inhibitor that blocks cell division for the treatment of glioblastoma and brain metastases originating from other cancers; and PAS-393, an immune-stimulatory cannabinoid designed to restore the immunogenicity of tumor cells with checkpoint inhibitor therapy for use in cancer treatment. It is also developing a B-cell targeted antibody for acute lymphoblastic leukemia and B cell lymphomas; and cannabinoid therapeutic products for the treatment of COVID-19. The company has an exclusive license agreement with the University of Washington to develop a cannabinoid-based product for the treatment of glioblastoma multiforme and brain metastases; and a collaborative research agreement with SoRSE Technology Corporation to advance PAS-393 into clinical testing. Pascal Biosciences Inc. was incorporated in 2011 and is headquartered in Seattle, Washington.

Full PSCBF Calculator →

QYLD — ETF

The Global X Nasdaq 100 Covered Call ETF (QYLD) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Cboe Nasdaq-100 BuyWrite V2 Index.

Full QYLD Calculator →

📬

Get this PSCBF vs QYLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PSCBF vs SCHD PSCBF vs JEPI PSCBF vs O PSCBF vs KO PSCBF vs MAIN PSCBF vs XYLD PSCBF vs JEPQ PSCBF vs RYLD

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.